News

JUPITER NEUROSCIENCES IN THE NEWS
  • media

    Jupiter Neurosciences, Inc. Announces Broadening of IP Estate for its Unique Resveratrol Formulation, JOTROLTM

    READ MORE
  • media

    Jupiter Announces Completion of Phase I Safety Trial with Enhanced Resveratrol Product, JOTROLTM

    READ MORE
  • media

    Jupiter Neurosciences, Inc. Expands its Executive Team

    READ MORE
  • media

    Jupiter Orphan Therapeutics Announces U.S. Patent for Its Resveratrol Formulation

    READ MORE
  • media

    Jupiter Orphan Announces Federal Grant to Advance JOTROLTM to Phase I Clinical Trial for Alzheimer’s

    READ MORE
  • media

    Professor Rudolph E. Tanzi, Ph.D., World Renowned Alzheimer’s Researcher, joins Jupiter Neurosciences

    READ MORE
  • media

    Jupiter Neurosciences receives Orphan Drug Designation for its trans-resveratrol product JOTROLTM for treatment of Friedreich’s Ataxia

    READ MORE
  • media

    Jupiter Neurosciences announces favorable data which expands JOTROL’s applications to the estimated $5 Billion mitochondrial rare disease market

    READ MORE
  • media

    Jupiter Neurosciences Secures Financing and Adds Board Member

    READ MORE
  • media

    Jupiter Neurosciences, Inc. receives Safe to Proceed Letter from FDA

    READ MORE
  • media

    Jupiter Neurosciences, Inc featured in Wall Street Journal

    READ MORE
  • media

    Jupiter Neurosciences Announces Submission of Investigational New Drug Application (IND) for Treatment of Mucopolysaccharidosis Type-I

    READ MORE
  • media

    Jupiter Neurosciences enters into a Global Licensing Agreement with Murdoch Childrens Research Institute for development of treatment for Friedreich’s Ataxia

    READ MORE
  • media

    Jupiter Neurosciences in Process to Submit IND for MPSI and Other Indications

    READ MORE